Correction of neuroimmune disorders in a post-viral chronic fatigue syndrome model using sodium deoxyribonucleate
Medical academic journal · 31.03.2026 · 26 (1) · 91-100
DOI: 10.17816/maj679228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical academic journal, online erschienen am 31.03.2026. Verfasst von Tatiana A. Filatenkova und 3 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Myalgic encephalomyelitis/chronic fatigue syndrome is defined as a chronic illness characterized by severe fatigue, sleep disturbances, memory and concentration issues, and malaise following physical exertion, often manifesting after a viral infection. Myalgic encephalomyelitis/chronic fatigue syndrome remains a poorly understood and difficult-to-diagnose condition for which pathophysiologically sound and effective treatments are still lacking. Experimental models of chronic fatigue syndrome, such as the Katafuchi model, allow the reproduction of key symptoms and enable evaluation of the effects of potential therapeutics on neuroimmune and behavioral parameters, providing a basis for the subsequent translation of these findings into clinical practice. AIM: To investigate the possibility of correcting manifestations of fatigue and neuroinflammation using a nucleotide-based drug (sodium deoxyribonucleate) in a model of chronic fatigue syndrome according to Katafuchi. METHODS: The study was conducted on 50 male Wistar rats. The disease was modeled through a single intraperitoneal administration of polyriboinosine-polyribocytidylic acid (Poly I:C) at a dose of 3 mg/kg body weight. Half of the subjects received sodium deoxyribonucleate on the first day after syndrome induction. On days 7 and 10 of the experiment, motor activity, emotional status, and physical fatigue levels were recorded. After sample collection, the concentration of lactic acid in plasma, the expression levels of genes (Il1b, Il10, Infα, 5Htt, Tlr3) in the hypothalamus, and the cytotoxic and proliferative activity of splenic lymphocytes as markers of immune system status were determined. RESULTS: A single administration of sodium deoxyribonucleate had a positive effect on metabolic processes (lactate levels after exercise), improved exploratory activity, reduced anxiety-like behavior, normalized the depressed cytotoxic and proliferative activity of splenic lymphocytes, and restored excessive expression of all studied genes in the hypothalamus to normal levels, which was not observed in untreated rats. CONCLUSION: Administration of sodium deoxyribonucleate to animals did not eliminate the characteristic muscle weakness but accelerated the normalization of physical activity and emotional status, reducing anxiety manifestations by day 7 of the experiment rather than day 10 as seen in the untreated rat group.
Zitieren
APA
Filatenkova, T. A., Shanin, S. N., Fomicheva, E. E., & Serebryanaya, N. B. (2026). Correction of neuroimmune disorders in a post-viral chronic fatigue syndrome model using sodium deoxyribonucleate. Medical academic journal, 26(1), 91-100. https://doi.org/10.17816/maj679228
Vancouver
Filatenkova TA, Shanin SN, Fomicheva EE, Serebryanaya NB. Correction of neuroimmune disorders in a post-viral chronic fatigue syndrome model using sodium deoxyribonucleate. Medical academic journal. 2026;26(1):91-100. doi:10.17816/maj679228
BibTeX
@article{Filatenkova2026,
author = {Filatenkova, Tatiana A. and Shanin, Sergey N. and Fomicheva, Elena E. and Serebryanaya, Natalia B.},
title = {Correction of neuroimmune disorders in a post-viral chronic fatigue syndrome model using sodium deoxyribonucleate},
journal = {Medical academic journal},
year = {2026},
volume = {26},
number = {1},
pages = {91--100},
doi = {10.17816/maj679228}
}
EUVIMED